Ranibizumab or Aflibercept for Diabetic Macular Edema Comparison of 1-Year Outcomes from the Fight Retinal Blindness! Registry

Affiliation auteurs!!!! Error affiliation !!!!
TitreRanibizumab or Aflibercept for Diabetic Macular Edema Comparison of 1-Year Outcomes from the Fight Retinal Blindness! Registry
Type de publicationJournal Article
Year of Publication2020
AuteursBhandari S, Nguyen V, Fraser-Bell S, Mehta H, Viola F, Baudin F, Gabrielle P-H, Creuzot-Garcher C, Gillies M, Barthelmes D
JournalOPHTHALMOLOGY
Volume127
Pagination608-615
Date PublishedMAY
Type of ArticleArticle
ISSN0161-6420
Résumé

{Purpose: Both ranibizumab and aflibercept improved vision and decreased macular thickness in eyes with diabetic macular edema (DME) in clinical trials. This study compared the 12-month treatment outcomes of each drug in routine clinical practice. Design: Retrospective analysis of data from the prospectively designed observational Fight Retinal Blindness! registry. Participants: Treatment-naive eyes tracked in the registry that initiated treatment with either ranibizumab (0.5 mg) or aflibercept (2 mg) for DME from December 1, 2013, through June 1, 2018. Methods: Visual acuity (VA) was analyzed at 12 months in all eyes (completers, noncompleters, and eyes that switched treatment). Main Outcome Measures: The primary outcome was the mean change in VA from baseline to 12 months. Results: We identified 383 eyes (ranibizumab
DOI10.1016/j.ophtha.2019.11.018